SCHEMBL29966734

SCHEMBL29966734

CC(C)C[C@H]1CCc2cc(O)ccc2[C@H]1c1ccc(N2CCC(C=O)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 17/20 0.44
ESR2 Q92731 11/20 0.44
CRBN Q96SW2 1/20 0.37
MLNR O43193 1/20 0.36
NR1I2 O75469 1/20 0.36
NR3C1 P04150 1/20 0.36
CHRM2 P08172 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRA2A P08913 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
CHRM1 P11229 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
CHRM3 P20309 1/20 0.36
SLC6A2 P23975 1/20 0.36
NPY1R P25929 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
AVPR2 P30518 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29966401 1.00 ESR1 (0.44) ESR1ESR2CRBNMLNRNR1I2
SCHEMBL30768821 0.90 ESR1 (0.41) ESR1ESR2CRBNMLNRNR1I2
SCHEMBL30769167 0.90 ESR1 (0.41) ESR1ESR2CRBNMLNRNR1I2
SCHEMBL30773568 0.88 ESR1 (0.40) ESR1ESR2CRBNDRD2DRD3
SCHEMBL31541204 0.88 ESR1 (0.46) ESR1ESR2CRBNMLNRNR1I2
SCHEMBL31541263 0.88 ESR1 (0.46) ESR1ESR2CRBNMLNRNR1I2
SCHEMBL27083141 0.87 ESR1 (0.39) ESR1ESR2CRBNMLNRNR1I2
SCHEMBL27081586 0.87 ESR1 (0.43) ESR1ESR2CRBNMLNRNR1I2
SCHEMBL29966494 0.87 ESR1 (0.43) ESR1ESR2CRBNMLNRNR1I2
SCHEMBL30768580 0.86 ESR1 (0.39) ESR1ESR2CRBNMLNRNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116917280-B Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2026-05-12 CN disclosed
US-20260098027-A1 PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) 2026-04-09 US disclosed
EP-4596538-A1 PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2025-08-06 EP disclosed
CN-120035586-A Pharmaceutically acceptable salts and crystal forms of tetrahydronaphthalene derivatives and preparation method thereof 江苏恒瑞医药股份有限公司 2025-05-23 CN disclosed
US-20250099596-A1 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2025-03-27 US disclosed
EP-4317146-A1 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-02-07 EP disclosed
CN-116917280-A Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2023-10-20 CN disclosed
WO-2022206737-A1 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098027-A1 PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD MDH2, MDH1, GOT1 ESR1 4671/4885ESR2 4648/4885CRBN 4349/4885
US-20250099596-A1 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE CYP51A1, CYP46A1, HSD17B11 ESR1 17/4885ESR2 33/4885CRBN 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.